ストックスクリーナーアプリを入手
184.74
1.40%
-2.63
Astrazeneca Plc (AZN) 最新ニュース
Astrazeneca Plc $AZN Shares Sold by D.A. Davidson & CO. - MarketBeat
UK's FTSE 100 slips as losses in energy stocks and AstraZeneca weigh - marketscreener.com
UK's FTSE 100 Closes Lower; NatWest, AstraZeneca Shares Down - marketscreener.com
Employee share plans add 14,807 AstraZeneca (AZN) shares to LSE - Stock Titan
FDA advisory committee does not support AstraZeneca’s camizestrant for breast cancer - Investing.com
AstraZeneca (AZN) Stock Drops as Breast Cancer Drug Fails to Win Over FDA Advisors - CoinCentral
FDA advisory panel recommends AstraZeneca’s Truqap for PTEN-deficient prostate cancer - Investing.com Nigeria
FDA panel opposes benefit-risk profile of AstraZeneca (AZN) camizestrant combo - Stock Titan
FDA panel supports AstraZeneca (NYSE: AZN) Truqap combo for PTEN-deficient prostate cancer - Stock Titan
FTSE 100 drops in thin trading as NatWest, AstraZeneca weigh - Moneycontrol.com
AstraZeneca wins FDA AdCom backing for Truqap (AZN:NYSE) - Seeking Alpha
AstraZeneca Prostate Drug Wins FDA Panel Backing As Breast Cancer Candidate Falters - Benzinga
AstraZeneca (NYSE: AZN) Posts Revenue Above $15bn in Q1 - Value The Markets
AstraZeneca Faces Setback as Drug Review Stirs Market Focus - Kalkine Media
AstraZeneca shares drop after US regulators vote against breast cancer drug - marketscreener.com
Why is AstraZeneca stock down today? - Traders Union
AstraZeneca falls as FDA advisers reject breast cancer drug use - Proactive financial news
AstraZeneca Shares Weaken After FDA Panel Rejects Camizestrant - Yahoo Finance UK
AstraZeneca PLC expected to post earnings of $2.58 a shareEarnings Preview - TradingView
AstraZeneca's Breast-Cancer Candidate Drug Loses FDA Panel Vote -- Update - marketscreener.com
AstraZeneca slips after FDA panel rejects breast cancer drug camizestrant By Investing.com - Investing.com Nigeria
AstraZeneca shares drop after US regulatory panel votes against breast cancer drug - Reuters
AstraZeneca shares dip after US regulatory panel rejects breast cancer drug - marketscreener.com
US FDA Committee Votes Against Combination Formulation Featuring AstraZeneca's Camizestrant - marketscreener.com
AstraZeneca's Truqap Recommended by US FDA's Oncologic Drugs Committee - marketscreener.com
AstraZeneca : Truqap recommended by FDA Advisory Committee for PTEN-deficient metastatic hormone-sensitive prostate cancer - marketscreener.com
Alger Growth & Income Portfolio's AstraZeneca PLC(AZN) Holding History - GuruFocus
AstraZeneca says Truqap recommended by FDA advisory committee for prostate cancer - marketscreener.com
ASTRAZENECA : Jefferies reiterates its Buy rating - marketscreener.com
ASTRAZENECA : Receives a Buy rating from JP Morgan - marketscreener.com
FDA Panel Votes Against Benefits of AstraZeneca's Breast Cancer Drug - marketscreener.com
FDA panel rejects risk-benefit profile of AstraZeneca cancer drug - Reuters
FDA Panel Votes Against Benefit of Astra’s Breast Cancer Drug - Bloomberg.com
AstraZeneca Is a Buy as More Than 20 Phase III Readouts Loom - 24/7 Wall St.
FDA panel votes against backing AstraZeneca's breast cancer drug - marketscreener.com
Complement Inhibitors Market Outlook Remains Strong During the Forecast Period (2026–2036) with Increasing Adoption of C5 and C3 Targeted Drugs | DelveInsight - GlobeNewswire Inc.
AstraZeneca's Breast Cancer Drug Rejected by FDA on Safety Concerns, Bloomberg Reports - marketscreener.com
AstraZeneca Earnings: Off to a Great Start, With Major Readouts Expected Throughout the Year - Morningstar Canada
Astrazeneca exercises option for Pinetree’s PTX-299 - BioWorld News
Citi raises AstraZeneca earnings forecast and maintains 'buy' rating ahead of second-half pipeline catalysts - Proactive financial news
AstraZeneca Outlook Strengthens on Pipeline Momentum - Kalkine Media
ASTRAZENECA : Deutsche Bank reaffirms its Sell rating - marketscreener.com
Pinetree Therapeutics Announces Exercise of Option to License EGFR Degrader Program by AstraZeneca - Quantisnow
AstraZeneca results: Q1 2026 - Quantisnow
AstraZeneca PLC (AZN) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic ... By GuruFocus - Investing.com Canada
EBIT per share of AstraZeneca PLC – HAM:ZEG - TradingView
Astrazeneca injects £300m into UK sites - marketscreener.com
Astrazeneca Q1 Earnings Call Highlights - Yahoo Finance
AstraZeneca takes global rights to an EGFR cancer drug in $25M deal - Stock Titan
AstraZeneca CEO says US MFN policy will have substantial impact on European drug launches, pricing - marketscreener.com
Correction to AstraZeneca Update - marketscreener.com
AstraZeneca Q1 2026 slides: pipeline delivers, revenue reporting raises questions - Investing.com
AstraZeneca plans to invest $405 million in Britain, PM Starmer says - marketscreener.com
AstraZeneca beats Q1 estimates, CEO says drug pipeline is 'delivering' - Yahoo Finance
AstraZeneca to make $405 million investment in Britain, PM Starmer says - marketscreener.com
AstraZeneca: Q1 Earnings Analysis: An Excellent Long-Term Buy And Hold (NYSE:AZN) - Seeking Alpha
What's Going On With AstraZeneca Stock Wednesday?AstraZeneca (NYSE:AZN) - Benzinga
AstraZeneca PLC 2026 Q1ResultsEarnings Call Presentation (NYSE:AZN) 2026-04-29 - Seeking Alpha
AstraZeneca revives Cambridge investment after UK agrees to pay more for drugs - Financial Times
Astrazeneca (AZN) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
AstraZeneca to inject £300 million into UK in surprise U-turn - Yahoo Finance UK
AstraZeneca to Invest £300 Million in UK in Boost for Starmer - Bloomberg.com
AstraZeneca: Desirable start to 2026, but most strengths are already priced in - marketscreener.com
AstraZeneca Plans to Invest $406 Million in U.K. - marketscreener.com
ASTRAZENECA : From Neutral to Buy by DZ Bank - marketscreener.com
Starmer: AstraZeneca to invest £300M in UK - Breakingthenews.net
BofA Maintains AstraZeneca at Buy After Q1 Sales Beat - marketscreener.com
What next for AstraZeneca shares, after another cracking quarter? - Fool UK
UK PM Starmer: AstraZeneca to invest 300 mln pound in UK - marketscreener.com
AstraZeneca (NYSE: AZN) posts Q1 2026 growth and major pipeline deals - Stock Titan
Shot in the arm for GSK and AstraZeneca from cancer drug sales - Yahoo Finance UK
AstraZeneca posts $15.3B sales after 14 approvals in major regions - Stock Titan
Why AstraZeneca (AZN) Stock Fell Despite Crushing Q1 Earnings Expectations - Blockonomi
ASTRAZENECA : From Neutral to Buy by Barclays - marketscreener.com
0.87%
2.73%
大文字化:
|
ボリューム (24 時間):